| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/09/2013 | CN101935349B Humanized monoclonal antibody against human vascular endothelial growth factor and preparation and application thereof |
| 01/09/2013 | CN101742999B Anti-fatigue agent and oral composition each comprising and rographolide as active ingredient |
| 01/09/2013 | CN101731506B Health-care food of bee glue and wood frog lecithin capsule |
| 01/09/2013 | CN101708302B Chinese medicinal preparation for treating diabetes and preparation method thereof |
| 01/09/2013 | CN101637255B Hypoglycemic nutrition powder |
| 01/09/2013 | CN101428009B Insulin intranasal inhalation powder spray |
| 01/09/2013 | CN101228131B 新的杂环亚基乙酰胺衍生物 New heterocyclic derivatives subunit acetamide |
| 01/09/2013 | CN101223158B N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| 01/09/2013 | CN101115735B Glucagon receptor antagonists, preparation and therapeutic uses |
| 01/08/2013 | US8349893 4-trimethylammonio-butyrates as CPT2 inhibitors |
| 01/08/2013 | US8349891 Crystalline solids of a MetAP-2 inhibitor and methods of making and using same |
| 01/08/2013 | US8349888 Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury |
| 01/08/2013 | US8349862 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia |
| 01/08/2013 | US8349836 Phthalazine derivatives as inhibitors of protein kinase |
| 01/08/2013 | US8349817 Analogues of cilostazol |
| 01/08/2013 | US8349331 Anti-interferon-α antibodies |
| 01/08/2013 | CA2742783C Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 01/08/2013 | CA2683751C Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| 01/08/2013 | CA2528591C Glp-1 analog fusion proteins |
| 01/08/2013 | CA2521987C Methods and compositions for increasing the anaerobic working capacity in tissues |
| 01/08/2013 | CA2521879C Process for resolving amines that are useful for the treatment of disorders associated with insulin resistance syndrome |
| 01/08/2013 | CA2507710C Tricyclic pyrazole derivatives and their use as cb1 or cb2 modulators |
| 01/08/2013 | CA2490121C Modified phospholipids |
| 01/08/2013 | CA2485081C Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 01/08/2013 | CA2478065C Macrocyclic compounds useful as pharmaceuticals |
| 01/08/2013 | CA2428782C Medicine based on anti-hyperglycaemic microcapsules with prolonged release and its method of preparation |
| 01/05/2013 | CA2745267A1 Iron supplement composition |
| 01/03/2013 | WO2013003641A2 Serpin fusion polypeptides and methods of use thereof |
| 01/03/2013 | WO2013002419A1 Mitochondrial disease-specific induced pluripotent stem cells, method of producing same and use thereof |
| 01/03/2013 | WO2013002313A1 Weight control drug |
| 01/03/2013 | WO2013001890A1 Soyasapogenol composition |
| 01/03/2013 | WO2013001819A1 SOLUBLE INTEGRIN α4 MUTANT |
| 01/03/2013 | WO2013001457A1 Novel salts of sitagliptin |
| 01/03/2013 | WO2013001310A1 Macrocyclic compounds and their use as cdk8 inhibitors |
| 01/03/2013 | WO2013000895A1 Dha and epa in the reduction of oxidative stress |
| 01/03/2013 | WO2013000275A1 C-glycoside derivatives |
| 01/03/2013 | WO2013000267A1 Azole heterocyclic compound, preparation method, pharmaceutical composition and use |
| 01/03/2013 | WO2013000108A1 Azole heterocylic compounds, preparation methods, pharmaceutical compositions and uses thereof |
| 01/03/2013 | WO2012170607A3 Use of pcsk9 antagonists |
| 01/03/2013 | WO2012150784A3 Novel indole derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic diseases containing same as active ingredient |
| 01/03/2013 | WO2012148140A3 Imidazole-based alkaloid derivatives which have angiogenesis inhibition and antioxidant effects and production method thereof |
| 01/03/2013 | WO2012145523A3 Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
| 01/03/2013 | WO2012140666A3 Herbal extracts and compositions prepared therefrom |
| 01/03/2013 | WO2012138146A9 Composition containing heat-treated powder or extract of glycine soja as active gradient for prevention and treatment of diabetes mellitus and diabetic complications |
| 01/03/2013 | WO2012134231A9 Benzamide derivative as cannabinoid receptor (cb1) antagonist |
| 01/03/2013 | US20130006351 Polymer coatings containing drug powder of controlled morphology |
| 01/03/2013 | US20130005820 Agomelatine hydrochloride hydrate and preparation thereof |
| 01/03/2013 | US20130005818 Glycogen or Polysaccharide Storage Disease Treatment Method |
| 01/03/2013 | US20130005814 Methods and compositions for facilitating weight loss by administration of thyroid hormones |
| 01/03/2013 | US20130005809 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130005790 Inorganic salt complexes of vildagliptin |
| 01/03/2013 | US20130005784 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| 01/03/2013 | US20130005783 Prevention And Treatment Of Diseases Caused By Elevated Levels Of Deoxy-Sphingolipids |
| 01/03/2013 | US20130005782 Method for integrin ligand discovery |
| 01/03/2013 | US20130005781 Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents |
| 01/03/2013 | US20130005779 Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
| 01/03/2013 | US20130005768 Compositions and methods for the treatment of metabolic disorders |
| 01/03/2013 | US20130005757 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| 01/03/2013 | US20130005755 Peripherally Acting Opioid Compounds |
| 01/03/2013 | US20130005743 New positive allosteric modulators of nicotinic acetylcholine receptor |
| 01/03/2013 | US20130005741 Substituted pyrimidine as a prostaglandin d2 receptor antagonist |
| 01/03/2013 | US20130005729 Metalloenzyme inhibitor compounds |
| 01/03/2013 | US20130005728 Substituted pyrimidines as prostaglandin d2 receptor antagonists |
| 01/03/2013 | US20130005721 Indolizine inhibitors of 5-lipoxygenase |
| 01/03/2013 | US20130005707 Aminotriazolopyridines, compositions thereof, and methods of treatment therewith |
| 01/03/2013 | US20130005706 Fused heterocyclic compounds as ion channel modulators |
| 01/03/2013 | US20130005705 Novel inhibitor compounds of phosphodiesterase type 10a |
| 01/03/2013 | US20130005703 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-ht6 receptor |
| 01/03/2013 | US20130005694 Liquid compositions comprising vitamin d and uses thereof |
| 01/03/2013 | US20130005689 Compounds for the treatment of addiction |
| 01/03/2013 | US20130005686 2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs |
| 01/03/2013 | US20130005679 Multivitamin Compositions and Methods for Improving Health |
| 01/03/2013 | US20130005675 Quinolone compound and pharmaceutical composition |
| 01/03/2013 | US20130005654 Therapeutic agent for accelerating recovery of animal under medical treatment |
| 01/03/2013 | US20130005652 Methods for administering long-lasting hypoglycemic agents |
| 01/03/2013 | US20130005651 Death associated protein 1 variants and use thereof for modulating autophagy |
| 01/03/2013 | US20130005649 Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| 01/03/2013 | US20130005646 Polypeptides |
| 01/03/2013 | US20130004604 Dark chocolate delivery system for a combination of dietary supplements and pharmaceuticals |
| 01/03/2013 | US20130004601 Appetite regulating dietary supplement |
| 01/03/2013 | US20130004596 Pharmaceutical composition for treating diabetes containing quamoclit angulata extract |
| 01/03/2013 | US20130004575 Controlled release formulations using intelligent polymers |
| 01/03/2013 | US20130004572 Stable pharmaceutical composition and methods of using same |
| 01/03/2013 | US20130004570 Nutritional supplement for use under physiologically stressful conditions |
| 01/03/2013 | US20130004568 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130004567 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130004566 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130004526 Utilization of Dialkylfumarates |
| 01/03/2013 | US20130004514 Therapeutic antibodies |
| 01/03/2013 | US20130004507 METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES |
| 01/03/2013 | US20130004491 Antibodies Against Phosphorylcholine In Combination Therapy with Biologic Agents |
| 01/03/2013 | US20130004465 Adherent cells from placenta and use of same in disease treatment |
| 01/03/2013 | US20130004452 Formulations Containing an Ionic Mineral-Ion Exchange Resin Complex and Uses Thereof |
| 01/03/2013 | US20130004434 Gastroretentive, Extended Release Composition Of Therapeutic Agent |
| 01/03/2013 | US20130004428 Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| 01/03/2013 | US20130004416 Dual Variable Domain Immunoglobulin and Uses Thereof |
| 01/03/2013 | CA2877102A1 Topical formulations including lipid microcapsule delivery vehicles and their uses |
| 01/03/2013 | CA2840806A1 Novel salts of sitagliptin |
| 01/03/2013 | CA2840626A1 Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence |
| 01/03/2013 | CA2840617A1 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |